A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486

Wyeth is now a wholly owned subsidiary of Pfizer0 sites30 target enrollmentNovember 2005

ConditionsArrhythmia

DrugsGAP-486 (ZP-123)0.9% Sodium Chloride, USP

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Arrhythmia
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 30
Primary Endpoint: This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.
Status: Terminated
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.

Registry

clinicaltrials.gov

Start Date

November 2005

End Date

October 2006

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion Criteria

•Patients with uncontrolled blood pressure
•Patients with certain cardiac risk factors
•Patients with significant kidney or liver problems

Outcomes

Primary Outcomes

This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.

Secondary Outcomes

This study takes place within 24 hours, and looks at the changes in values of electrophysiology studies, before and after administration of test article.